Assessment of patient, consumer and healthcare professional organisations compliance with EMA eligibility criteria

Similar documents
Delivery time frame for the EU portal and EU database

Work plan for GCP Inspectors Working Group for 2018

European network of paediatric research (EnprEMA)

Questions and answers on the procedure of PIP compliance verification at EMA, and on paediatric rewards

Guidance for the conduct of good clinical practice inspections

Patient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force

Standard operating procedure

European network of paediatric research (Enpr-EMA)

Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol

A Dedicated Post Authorisation Measure Submission Form

Standard operating procedure

EV Reporting process for users: Creating and sending ICSRs using EVWEB part II

European network of paediatric research (EnprEMA)

Remediation, Resolution and Outcomes

Guidance for applicants requesting scientific advice

Guideline for Research Programmes Rules for the establishment and implementation of programmes falling under the Programme Area Research

EUROPEAN COMMISSION DIRECTORATE-GENERAL JUSTICE

Transmission to CHMP December Adoption by CHMP for release for consultation December 2008

Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics Oslo

Use of disease registries for benefitrisk evaluation of medicines: A regulatory perspective. DIA Europe April Basel, Switzerland

GUIDE FOR APPLICANTS. SUPPORT TO EUROPEAN COOPERATION PROJECTS 2018 and COOPERATION PROJECTS RELATED TO THE EUROPEAN YEAR OF CULTURAL HERITAGE 2018

Answers to questions following the call for tender for a Fund Operator for the EEA and Norway Grants Global Fund for Regional Cooperation

Sub-granting. 1. Background

Medical devices briefing for patients: Patient safety in the new Regulation

The Dialogue Facility THE DIALOGUE FACILITY Bridging Phase Guidelines and Criteria for Support

Frequently Asked Questions EU Aid Volunteers Initiative

Lessons from the EMA Patient Registries Initiative

BEST PRACTICE GUIDE FOR DECENTRALISED AND MUTUAL RECOGNITION PROCEDURES

General FAQ relating to e-submission for Veterinary Applications

Clinical data Publication Webinar

Continuous Professional Development of Health Professionals European Context

EPF recommendations for the trilogue on the proposal for regulation on Medical Devices

Regulation on the implementation of the European Economic Area (EEA) Financial Mechanism

Adopted by Pharmacovigilance Risk Assessment Committee 20 February Adopted by Pharmacovigilance Inspectors Working Group 21 March 2014

ERASMUS MUNDUS Frequently-asked questions ACTION 2: Questions from higher education institutions Latest update: January 2011

Guideline on good pharmacovigilance practices (GVP)

Grünenthal Norway AS - Methodological Note

COMMISSION IMPLEMENTING REGULATION (EU)

2011 Call for proposals Non-State Actors in Development. Delegation of the European Union to Russia

Heritage Grants - Receiving a grant. Mentoring and monitoring; Permission to Start; and Grant payment

NOTICE OF CALL FOR PROPOSALS WITH A VIEW TO OBTAINING GRANTS IN THE FIELD OF MARITIME TRANSPORT

Study definition of CPD

Republic of Latvia. Cabinet Regulation No. 50 Adopted 19 January 2016

NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE

CREATIVE EUROPE ( ) Culture Sub-programme. Call for proposals : EACEA 32/2014 : European cooperation projects

EUROPEAN COMMISSION Executive Agency for Small and Medium-sized Enterprises (EASME)

Continuing Medical Education (CME) Endorsement Application Guide

TASMANIAN HEALTH ASSISTANCE PACKAGE: BETTER ACCESS TO PALLIATIVE CARE IN TASMANIA PROGRAM INVITATION TO APPLY FOR FUNDING ITA No.

Annual report of the Good Clinical Practice Inspectors Working Group 2016

Open call for proposals VP/2004/021. Initiatives to promote gender equality between women and men, including activities concerning migrant women

This policy applies to all staff and contractors working for the Agency and all persons working within its demised premises.

Patient Registries Initiative Background, Achievements, Next steps

Transatlantic Strategy Forum

How to register under the Health and Social Care Act 2008

Call for Proposals from non-for-profit organizations

Code of practice on relationships between the research-based pharmaceutical industry and patient organizations in Bulgaria

Draft EU Guidance on Medication Errors

ANNEX III FINANCIAL AND CONTRACTUAL RULES I. RULES APPLICABLE TO BUDGET CATEGORIES BASED ON UNIT CONTRIBUTIONS

Questions and answers about Recycling Processes

Office of the District of Columbia Auditor

Brussels, 19 December 2016 COST 133/14 REV

BASG / Austrian Medicines and Medical Devices Agency Institute Assessment & Analytics Traisengasse 5, A-1200 Vienna

FREQUENTLY ASKED QUESTIONS (FAQ)

Annex 3 Information and Communication Requirements EEA and Norway Grants

ICH Topic Q4B Annex 6 Uniformity of Dosage Units General Chapter. Step 3

CODE OF CONDUCT Q&A. Medicines for Europe. Follow us on

Preparatory action. ERASMUS for young entrepreneurs ENT/ERA/10/411

Application for Membership of The Association of the British Pharmaceutical Industry

REACH Pre-registration Questions and Answers

CALL FOR PROPOSALS LOCAL INITIATIVES ON INTER-MUNICIPAL COOPERATION IN MOLDOVA

Procedure for handling applications for authorisation and review reports under REACH

How Will Europe s New Medtech Code Affect Your Meetings?

Gambling Community Benefit Fund Program Instructions for submitting grant applications using the Online Grants Portal

EMA Patients and Consumers Annual Training Overview:

Appendix 3 to AO/1-7094/12/NL/CO Page 1

Lottery Capital Programme. Help Notes. Feasibility Study

EUROPEAN FEDERATION OF NURSES ASSOCIATIONS (EFN) CONSTITUTION

Trustees review of structure and effectiveness: proposed amendments to the IFRS Foundation constitution

Restricted Call for proposals addressed to National Authorities for Higher Education in Erasmus+ programme countries

COMMISSIONING SUPPORT PROGRAMME. Standard operating procedure

"ERA-NET Plus Actions"

INTEGRATION SCHEME (BODY CORPORATE) BETWEEN WEST DUNBARTONSHIRE COUNCIL AND GREATER GLASGOW HEALTH BOARD

DESIGN COMPETITION GUIDELINES

Workforce Development Fund

List of nationally authorised medicinal products

Minutes of EMA Human Scientific Committees Working Party with Patients and Consumers Organisations (PCWP) meeting with all eligible organisations

HERCULE III PROGRAMME CALL FOR PROPOSALS REF. Hercule III 2014 ANTI-FRAUD TRAINING E PROGRA MME ANTI-FRAU

Horizon ERA-NET Cofund actions

[Enter Organization Logo] CONSENT TO DISCLOSE HEALTH INFORMATION UNDER MINNESOTA LAW. Policy Number: [Enter] Effective Date: [Enter]

Home Energy Saving (HES) scheme - Homeowner Application Form Version 10.0

WORK PROGRAMME 2012 CAPACITIES PART 2 RESEARCH FOR THE BENEFIT OF SMES. (European Commission C (2011)5023 of 19 July)

Guideline on good pharmacovigilance practices (GVP)

Community Child Care Fund - Restricted non-competitive grant opportunity (for specified services) Guidelines

CMDv/BPG/002. BEST PRACTICE GUIDE for Veterinary Decentralised Procedure (DCP)

CALL FOR PROPOSALS. Dissemination activities for the Council of Europe Reference Framework of Competences for Democratic Culture. Reference 2018/RFCDC

IATI Implementation Schedule for: Plan International USA

Call for Proposal EACEA/07/2017 Erasmus+ Programme KA3 Support for Policy Reform. Social Inclusion through Education, Training and Youth

CONTRACT SPECIFICATION

R. Fay, Research Governance & GCP Manager K. Mahiouz, Clinical Trials Facilitator E. Clough, R&D Governance Operations Manager

4. Multi Stakeholder: Late & Early Dialogue

Transcription:

15 March 2018 EMA/698917/2017 Stakeholders and Communication Division Assessment of patient, consumer and healthcare professional organisations compliance with EMA eligibility criteria 1. Introduction and purpose As defined within the frameworks for interaction, the Agency endeavours to establish and maintain a network of European patient, consumer and healthcare professional organisations to foster consistent and targeted interactions with a broad range of organisations across Europe with diverse expertise and interests. Eligibility criteria for selection of organisations (link to be added) have been established to ensure that the Agency works with the most appropriate organisations. Organisations may submit an application for eligibility at any time and, provided the criteria defined herein are met, they become part of the Agency s network of European organisations listed on the Agency website, and are the first point of contact for involvement in EMA activities, as and when appropriate. The purpose of this document is to explain how obtained from each organisation during the Agency s assessment of eligibility, is assessed to conclude whether that organisation is eligible. 2. Scope This policy applies to patient, consumer and healthcare professional organisations. It does not apply to individual patients, consumers and healthcare professionals when they act as experts or committee members. Participation as experts and committee members is ruled by the EMA policy on conflict of interests (link). 3. Assessment of criteria for new applications 3.1. Pre-assessment When a new organisation applies for eligibility, a pre-assessment is undertaken to confirm that the organisation has a not-for-profit status and fits within the definitions set out for patient, consumer or healthcare professional organisations: 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5505 Send a question via our website www.ema.europa.eu/contact An agency of the European Union European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.

Patient organisations are defined as not-for profit organisations which are patient focused, and in which patients or carers (the latter when patients are unable to represent themselves) represent a majority of members in their governing bodies. Consumer organisations are defined as not-for profit organisations which defend and promote the general interests of European consumers - citizens as purchasers or users of goods and services. Healthcare professional organisations are defined as not-for-profit organisations that have an interest in patient care, and where healthcare professionals represent a majority of members in their governing bodies. Definition Requirement Mandatory website How is Not-for-profit status Focus of the organisation Governing bodies Completed application form Registered status/ bylaws/ constitution/ terms of reference, etc. A clear reference to the non-profit status Registered status/ bylaws/ constitution/ terms of reference, etc. and available on the organisation's website non-profit status is justified, and focus of the organisation and representation in governing bodies comply with the definition If these conditions are met a full assessment is carried out as highlighted below. 3.2. Fulfilment of criteria The following table outlines how each criterion is assessed for compliance: Criterion Requirement Mandatory website How is Legitimacy Statutes registered in a Member State of the EU/EEA OR If statutes registered outside EU/EEA, there is a branch or office operating within EU/EEA Registered status/ bylaws/ constitution/ terms of reference, etc. and on the organisation website The organisation has registered status within EU/EEA and/or EMA/698917/2017 Page 2/9

Criterion Requirement Mandatory website How is and/or membership covers at least 50% of all EU/EEA Member States Has a branch or office operating within EU/EEA and/or Has membership covering at least 50% of all EU/EEA Member States Mission/ objectives Mission and objectives are clearly stated in official documents/ website and are linked to patient care and/or medicines Mission and objectives and on the organisation website its mission and objectives include: Summary text for publication on EMA website is provided as part of application Patient care and interests Activities with an interest in medicines and the Agency s work Activities Specific interests in medicines documented as part of organisation activities Annual activity reports and/or other forms of reporting /documenting specific interests in medicines included on organisation website Activities have EU focus and outreach Annual activity reports and/or other forms of reporting/ documenting specific interests in medicines Information on the organisation website is assessed in terms of: How the scope of activities relates to its mission/objectives Whether specific interests in medicines are documented as part of the organisation activities EU focus and outreach In the case of reevaluation: References to work with the Agency EMA/698917/2017 Page 3/9

Criterion Requirement Mandatory website How is Representation 1 Member associations are listed on the organisation s website Information provided to EMA should include the geographic distribution (country coverage) of individual members, if applicable Structure Governing bodies are elected by their members, who shall be patients, or consumers, or their elected representatives or healthcare professionals Governance structure clearly described in publically available, including all categories of membership Voting members of governing bodies or in executive functions are not employed by an individual company or association representing commercial manufacturers of medicines, healthcare products, medical List of member associations Strongly recommended: Geographical distribution of individual members, if applicable Clear description of the Governance structure (e.g. via publication of status/bylaws) List of corporate members, if applicable Information on organisation website is assessed in terms of: Organisation is representative of patients, consumers or healthcare professionals throughout EU/EEA Organisations already registered at Union level, e.g. in EU Health Forum or Council of Europe, are considered to be representative and available on the organisation website A procedure is in place for electing members of governing bodies Elected members of governing bodies are overall representative of the organisation Corporate members, if part of governing bodies, do not have voting rights 1 Applications from national organisations may be considered exceptionally in case of lack of European associations for a specific disease or treatment area; if similar associations exist in different MS, a choice will be considered on a case-by-case basis; Applications from international organisations can be considered as long as membership is representative of EU/EEA countries. EMA/698917/2017 Page 4/9

Criterion Requirement Mandatory website How is devices; or distributors and wholesalers; or consultants providing services to a company or industry association Accountability and consultation modalities Statements and opinions of the organisations reflect the views and opinions of its members Adequate consultation procedures are in place Appropriate flow of is in place to allow dialogue from and towards its members (e.g. announcements on the website; interactive on-line members area; through email and meetings, etc.) Description of policy and decision-making procedures and/or available on the organisation's website Procedures are in place for consultation and communication with all members of the organisation Transparency Completion of EMA funding sources table with detailed on all sources of income (both in absolute terms and in terms of overall percentage of the organisation s income). See 3.3 for full details of requirements Disclosure of the latest official annual financial statement (approved by the organisation s governing bodies as per its status/bylaws) Proof that the organisation s accounts are annually audited, if available Full transparency is encouraged (and The below should be published following approval of annual accounts : List of all funding sources (industry and non-industry) Overall proportion of industry and non-industry funding Percentage of the highest contribution from a single company (in terms of the overall income) Strongly recommended: Latest official annual financial and on the organisation's website The EMA funding sources table reflects as much as possible the included in the organisation s official financial statement Organisation accounts are annually audited, if available Financial including source(s) of funding, both public and private is published in the organisation s EMA/698917/2017 Page 5/9

Criterion Requirement Mandatory website How is minimum all the aforementioned publishing requirements must be met) Code of conduct/policy 2 regulating its relationship with and independence from the sponsors is disclosed to the EMA or is made publically available statement Code of conduct/policy regulating its relationship with and independence from the sponsors website Where industryrelated funding exceeds 20% of the total income: This must be from at least 3 separate companies, and The contribution from a single company should not reach the majority of the organisation s total income See 3.3 for full details of financial requirements The organisation should meet overall transparency requirements by ensuring that all subject to publication is available on their website 3.3. Financial statements and completion of the funding sources table For the evaluation of financial, organisations are asked to complete an EMA template table of funding sources (see completed example below) and also provide their official financial statement (and auditors report if available) for the year covered by the assessment. As part of the evaluation for eligibility, the Agency will assess the financial received against the following set of parameters: 1. Diversity of funding; if funding received from pharmaceutical companies exceeds 20% of the organisation s total funding, this must be from at least 3 separate companies and the individual contribution from a single company should not reach the majority of the organisation s total funding (including non-pharmaceutical industry funding). 2. Latest official financial accounts/report made available to the Agency. 2 Such document should outline the basic principles governing relations between the organisation and industry (regardless of receipt of funds) when engaging in a dialogue, working partnership, joint initiative and/or sponsorship. EMA/698917/2017 Page 6/9

3. The organisation s funding sources are made public on its website. 4. The existence of a code of conduct/policy regulating the organisation relations with and independence from the pharmaceutical industry. In order for an organisation to be considered eligible, all four parameters must be met. Depending on the organisation s approval schedule, a final financial statement may not be available at the time of submitting the evaluation form. In this case, they should provide a draft financial statement, advising when the final official statement is expected to be approved and as soon as the final document is available forward it to the Agency which will then finalise the evaluation. The table of funding sources is expected to reflect as much as possible the contained in the official financial statement, as these documents are reviewed in conjunction. This, once assessed against the set of parameters identified above will remain valid throughout the year regarding participation in activities which do not involve specific product-related evaluation or discussion. Organisations must inform the Agency of any change at any time that could affect their eligibility. Below is a description of what is expected to be included under the industry related and non-industry related sections of the table of funding sources: Industry related income Income originating from: Any individual company or association representing commercial manufacturers of medicines as well as healthcare products, medical devices and services; Distributors and wholesalers; Consultants providing services to a company or industry association, including PR firms. Should reflect the overall funding received from industry (used for overall internal operation of the organisation or any of its activities): Fees for corporate memberships; Sponsorship, donations and/or unrestricted grants for projects, conferences, or training; etc. For organisations with an extensive amount of sponsors (e.g. > 50), the Agency may be prepared to discuss alternative methods of confirming the data. Non-industry related income Income originating from: All other sources not falling within the definition of industry-related income (e.g. public or private institutes/ bodies; banks). Should reflect the overall funding received from any other sources (used for overall internal operation of the organisation or any of its activities): Membership fees; Sponsorship, donations and/or unrestricted grants from non-industry entities for projects, conferences, training, etc.; EMA/698917/2017 Page 7/9

Royalties for publications; Sale of educational materials/guidelines; Bank interests; Investment income (if managed by a third party, this should be stated and no further is required; otherwise, the organisation will have to confirm in writing that the investment portfolio excludes pharmaceutical companies or include it under industry-related income); Income from congresses and other meetings (if managed via a professional congress organiser (PCO) and whereby the organisation receives a percentage of the net income), etc. Example of a completed funding sources table: Industry related income Name of company/funder Amount of income Percentage of overall income Company A 1500 17.34% Company B 1000 11.56% Company C 700 8.10% Subtotal: 3200 37.00% Non-Industry related income Source of funding Amount of income Percentage of overall income Membership fees 4000 46.24% EU funded project XYZ 1000 11.56% Bank interests 450 5.20% Subtotal: 5450 63.00% 4. Annual re-assessment of eligibility Annually each eligible organisation is required to perform a self-declaration of eligibility to confirm that they remain compliant with the criteria. The organisations complete and submit an electronic form (automatically sent to them via the stakeholder database) whereby they confirm compliance with each of the 7 eligibility criteria (series of tick boxes) as well as funding aspects. Once submitted there will be a validation phase by EMA and if the organisation continues to comply with all criteria (as confirmed within the form) they will receive a confirmation of compliance and the organisation will continue to be part of the group of EMA eligible organisations as listed on the EMA website. EMA/698917/2017 Page 8/9

Each year a random selection of up to 20% of patient/consumer and healthcare professional organisations (up to 20% each category) will be performed using excel formula and the selected organisations will be subject to a full evaluation of compliance with the eligibility criteria. Assessed organisations will be removed from the organisation assessment list during the following year 5. Related documents Criteria to be fulfilled by patient, consumer and healthcare professional organisations involved in European Medicines Agency (EMA) activities (EMA/MB/24913/2005, Rev 3). EMA/698917/2017 Page 9/9